[{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"}]

Find Clinical Drug Pipeline Developments & Deals for ORIC-101

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 10, 2021

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 plasma concentrations provided excellen...

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 06, 2021

                          Lead Product(s) : ORIC-101,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The data demonstrate that GR may be a mechanism of resistance to AR degraders and that in vitro, ORIC-101 overcomes GR-driven resistance to AR degradation.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 10, 2020

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : ORIC-101 overcame GR-mediated resistance to chemotherapeutic agents including taxanes, antimetabolites and platinums, in both in vitro and in vivo efficacy studies spanning a variety of solid tumor types.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 22, 2020

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The IPO proceeds will push ORIC Pharma's lead program through phase 1b and into phase 2 and move its second program into the clinic.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 23, 2020

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : $120.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The funding is directed towards company's advancing pipeline of drug candidates for the treatment of prostate cancer and solid tumors.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 20, 2020

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : $75.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.

                          Product Name : ORIC-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2020

                          Lead Product(s) : ORIC-101,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank